Escherichia coli Isolated from Urinary Tract Infections of Lebanese Patients between 2000 and 2009: Epidemiology and Profiles of Resistance

Table 5

Susceptibility profiles of ESBL producing E. coli collected from Lebanese patients between 2005 and 2009 at the Saint George Hospital-University Medical Center, Beirut.

		Percentages of susceptibility of ESBL producing E. coli
		Antibacterial agent
Year	Isolates	Amikacin	Cefoxitin	Gentamycin	Pip + Tazo	TSM	Tigecycline	Ciprofloxacin
2005	All	90.5	85.6	29.8	97.6	39.4	ND	21.1
	Urinary	92.3	87.6	35.2	97.5	41.1	ND	16.4
	Nonurinary	88.2	83.5	25.1	97.8	37.1	ND	17.9
2006	All	97.9	80.7	27.3	93.3	24.1	ND	17.6
	Urinary	95.6	84.4	33.5	94.1	40.8	ND	18.8
	Nonurinary	98.3	76.9	22.1	93.5	18.9	ND	16.5
2007	All	93.6	81.4	30.1	92.2	23.5	89.6	23.1
	Urinary	91.2	87.5	22.4	89.9	36.8	91.2	25.7
	Nonurinary	90.2	75.6	36.8	95.4	41.3	93.2	19.1
2008	All	94.2	80.6	27.8	94.1	25.6	87.4	18.8
	Urinary	89.1	82.4	24.4	87.9	26.6	91.4	21.1
	Nonurinary	97.3	77.1	32.2	98.8	23.9	82.1	15.5
2009	All	93.6	83.4	30.8	94.2	19.5	91.6	19.6
	Urinary	94.6	84.5	36.1	96.6	25.4	94.4	19.5
	Nonurinary	91.8	82.2	26.3	92.2	10.6	89.9	19.2